This observation is in line with the increase in the number of anti-malarial clinical efficacy trials reported in the literature in recent years [77] and likely reflects the growing prioritization and feasibility of surveillance as a component of malaria control strategies. S108N) genotype anddhpsdouble mutant (A437G and K540E) genotype in Africa. A hierarchical mixed effects logistic regression was used to examine the influence of various Amicarbazone factors on reported mutant genotype frequency. These factors include: 12 months and location of study, age and clinical status of sampled populace, and reporting conventions for mixed genotype data. == Results == A database consisting ofdhfranddhpsmutant genotype frequencies from all African studies that met selection criteria was created for this analysis. The map illustrates particularly high prevalence of both thedhfrtriple anddhpsdouble mutant genotypes along the Kenya-Tanzania border and Malawi. The regression model shows a statistically significant increase in the prevalence of both thedhfrtriple Amicarbazone anddhpsdouble mutant genotypes in Africa. == Conclusion == Increasing prevalence of thedhfrtriple mutant anddhpsdouble mutant genotypes in Africa are consistent with the loss of efficacy of SP for treatment of clinical malaria in most parts of this continent. Continued assessment of the effectiveness of SP for the treatment of clinical malaria and intermittent preventive treatment in pregnancy is needed. The creation of a centralized resistance data network, such as the one proposed by the WorldWide Antimalarial Resistance Network (WWARN), will become a valuable source for planning timely actions to fight drug resistant malaria. == Background == == The malaria problem == Global malaria control initiatives have a turbulent history driven by a number of biological, social, and economic factors. The Malaria Eradication Programme launched by the World Health Business (WHO) in 1955 successfully eliminated malaria in many temperate and sub-tropical regions of the world, but little progress was made in sub-Saharan Africa. The programme confronted technical difficulties including, but not limited to: anti-malarial drug resistance, insecticide resistance, lack of infrastructure to implement and sustain control steps, and a lack of community engagement and participation [1]. These obstacles collectively damaged the long-term sustainability of the eradication programme, which was ultimately forgotten in 1969 [2]. The renewed vision for malaria control and eventual removal focuses on the development of new tools and improved integration of existing interventions [3]. Financing from your Global Fund to Fight AIDS, Tuberculosis, and Malaria; the World Bank Malaria Booster Program; and the U.S. President’s Malaria Initiative (PMI) have increased funding for malaria control. One objective of the PMI includes a 50% reduction in malaria mortality in 15 African countries over a five-year period by expanding the protection of effective interventions including: insecticide-treated mosquito nets (ITNs), indoor residual spraying with insecticides, intermittent preventive treatment for pregnant women (IPTp), and artemisinin-based combination therapy (Take action) [3,4]. Take action is a vital component of the malaria control strategy and currently represents the last line of defense against infections that have developed resistance to previous anti-malarial therapies. Chloroquine (CQ) monotherapy was highly effective in treating malaria for several years, but eventual appearance of CQ resistance toP. falciparumbecame a major challenge for control programs [5-8]. The onset of pervasive CQ resistance led to its replacement with anti-folate drugs, most notably sulphadoxine-pyrimethamine (SP), as a first-line therapy in many parts of the world. However, resistance to anti-folate drugs emerged rapidly. Take action has since been launched to either work in combination with anti-folates or replace them as first-line therapies in many settings, reviewed in [9,10]. == Monitoring anti-malarial drug resistance == Drug resistance continues to present a major threat to leftover effective anti-malarial therapies, such as ACT, that currently serve as a cornerstone of Amicarbazone the malaria control strategy. Therefore, the success of control efforts relies heavily upon surveillance methods to properly monitor and promptly respond to emerging resistance. Clinical efficacy trials that measure the therapeutic failure rate following administration of a particular drug are the gold-standard method for gauging the effectiveness of anti-malarial therapies. However, clinical efficacy trials are resource-intensive, making them hard to use broadly for surveillance purposes, reviewed in [11]. Translating a measure of Amicarbazone drug efficacy into a reliable assessment of drug resistance is also obscured by a number of host, drug, and parasite factors LEFTY2 such as: acquired immunity [12], compliance dosing [13], nutritional status [14], pharmacokinetics [15], parasite synchronicity and biomass [16], and endogenous parasite.